Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

Study Identifier
198027-A
CT.gov Identifier
NCT01987765
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Conjunctivitis
    • Study Drug
  • Relestat Ophthalmic Solution 0.05%
    • Phase
    N/A
    Sex
    Female & Male
    Age
    N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in clinical practice.
    Exclusion Criteria:
    * None.

    Protocol Summary

    This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.

    Study Locations

    Location
    Status
    Location
    Gangwon-do, Republic of Korea
    Status
    Not applicable